Voyager Therapeutics Inc (NASDAQ:VYGR) Expected to Post Quarterly Sales of $5.25 Million

Wall Street brokerages expect that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce sales of $5.25 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Voyager Therapeutics’ earnings. The lowest sales estimate is $2.00 million and the highest is $11.00 million. Voyager Therapeutics posted sales of $2.58 million during the same quarter last year, which suggests a positive year over year growth rate of 103.5%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Voyager Therapeutics will report full year sales of $29.94 million for the current financial year, with estimates ranging from $5.00 million to $81.57 million. For the next year, analysts forecast that the business will post sales of $52.20 million, with estimates ranging from $7.60 million to $95.57 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($1.46). Voyager Therapeutics had a negative net margin of 804.55% and a negative return on equity of 129.67%. The company had revenue of $5.20 million during the quarter, compared to analyst estimates of $3.00 million.

A number of analysts have weighed in on the stock. Morgan Stanley upgraded shares of to an “overweight” rating and set a GBX 400 ($5.23) target price on the stock in a research report on Friday. HC Wainwright raised their target price on shares of Cytokinetics from $21.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Nomura raised their target price on shares of Voyager Therapeutics from $26.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. ValuEngine upgraded shares of Yelp from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Finally, Wedbush restated an “outperform” rating and issued a $74.00 target price on shares of Tempur Sealy International in a research report on Tuesday, June 18th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $27.44.

Voyager Therapeutics stock traded down $0.17 during mid-day trading on Friday, reaching $25.50. The company had a trading volume of 433,299 shares, compared to its average volume of 512,757. Voyager Therapeutics has a fifty-two week low of $7.76 and a fifty-two week high of $28.79. The firm has a market cap of $945.49 million, a P/E ratio of -9.27 and a beta of 2.57. The company has a fifty day moving average of $25.27.

Hedge funds have recently added to or reduced their stakes in the company. SG3 Management LLC bought a new position in shares of Voyager Therapeutics during the first quarter valued at $57,000. BNP Paribas Arbitrage SA raised its stake in shares of Voyager Therapeutics by 74,766.7% during the first quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $86,000 after acquiring an additional 4,486 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Voyager Therapeutics by 449.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after acquiring an additional 7,401 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Voyager Therapeutics by 211.0% during the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after acquiring an additional 7,217 shares during the last quarter. Finally, AlphaCrest Capital Management LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at $102,000. 73.78% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Further Reading: What is an overbought condition?

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.